AAAAAA

   
Results: 1-9 |
Results: 9
Clinical trial designs for cytostatic agents - Reply
Authors: Korn, EL Arbuck, SG Pluda, JM Simon, R Kaplan, RS Christian, MC
Citation: El. Korn et al., Clinical trial designs for cytostatic agents - Reply, J CL ONCOL, 19(12), 2001, pp. 3154-3155
Clinical trial designs for cytostatic agents: Are new approaches needed?
Authors: Korn, EL Arbuck, SG Pluda, JM Simon, R Kaplan, RS Christian, MC
Citation: El. Korn et al., Clinical trial designs for cytostatic agents: Are new approaches needed?, J CL ONCOL, 19(1), 2001, pp. 265-272
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma
Authors: Janik, JE Miller, LL Korn, EL Stevens, D Curti, BD Smith, JW Sznol, M Conlon, KC Sharfman, W Urba, WJ Gause, BL Longo, DL
Citation: Je. Janik et al., A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma, BLOOD, 97(7), 2001, pp. 1942-1946
Analyzing health surveys for cancer-related objectives
Authors: Graubard, BL Korn, EL
Citation: Bl. Graubard et El. Korn, Analyzing health surveys for cancer-related objectives, J NAT CANC, 91(12), 1999, pp. 1005-1016
Another look at two phase I clinical trial designs - Commentary
Authors: Korn, EL Midthune, D Chen, TT Rubinstein, LV Christian, MC Simon, RM
Citation: El. Korn et al., Another look at two phase I clinical trial designs - Commentary, STAT MED, 18(20), 1999, pp. 2691-2692
Data monitoring committees and interim monitoring guidelines
Authors: Freidlin, B Korn, EL George, SL
Citation: B. Freidlin et al., Data monitoring committees and interim monitoring guidelines, CONTR CL TR, 20(5), 1999, pp. 395-407
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
Authors: Miller, LL Korn, EL Stevens, DS Janik, JE Gause, BL Kopp, WC Holmlund, JT Curti, BD Sznol, M Smith, JW Urba, WJ Donegan, SE Watson, TM Longo, DL
Citation: Ll. Miller et al., Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin, BLOOD, 93(10), 1999, pp. 3250-3258
Predictive margins with survey data
Authors: Graubard, BI Korn, EL
Citation: Bi. Graubard et El. Korn, Predictive margins with survey data, BIOMETRICS, 55(2), 1999, pp. 652-659
Truncated logistic regression and residual intracluster correlation
Authors: Midthune, DN Korn, EL Graubard, BI
Citation: Dn. Midthune et al., Truncated logistic regression and residual intracluster correlation, BIOMETRICS, 54(3), 1998, pp. 1193-1195
Risultati: 1-9 |